Genetic cancer vaccines: Current status and perspectives

Expert Opinion on Biological Therapy

Volumn 12, Issue 8, 2012, Pages 1043-1058

  Aurisicchio, Luigi ^a,b   Ciliberto, Gennaro ^c  

^a Takis   (Italy)

^b Grande Ospedale Metropolitano   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

cancer vaccines; plasmid DNA; tumour associated antigens; viral vectors

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CV 9103; CV 9201; DNA VACCINE; ETBX 011; INTERLEUKIN 1; IPILIMUMAB; ISF 35; JX 594; MKC 1106; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MONOCLONAL ANTIBODY; MVA BNO HER2; MVA BNO PRO; ONCEPT; SIPULEUCEL T; TG 4010; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID; VGX 3100; VIRUS VECTOR;

ADVANCED CANCER; ALPHA VIRUS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL THERAPY; DISEASE CONTROL; DRUG EFFICACY; ELECTROPORATION; GENE VECTOR; GENETIC CODE; GENETIC IMMUNIZATION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POXVIRUS; PROSTATE CANCER; REVIEW; UTERINE CERVIX CANCER;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNIZATION SCHEDULE; NEOPLASMS; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84863795689     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.689279     Document Type: Review

References (101)

1. Domschke C, Schuetz F, Ge Y, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009;69:8420-8
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9
3. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol 2011;186:1325-31
4. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: Are we there yet? Immunol Rev 2011;239:27-44
5. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology- analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711-19
6. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-40
7. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: Genetic modification to redirect effector cell specificity. Cancer J 2010;16:336-41
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
9. Culver ME, Gatesman ML, Mancl EE, Lowe DK. Ipilimumab: A novel treatment for metastatic melanoma. Ann Pharmacother 2011;45:510-19
10. Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2010;11:1354-9
11. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
12. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA approved ther cancer vaccine. Clin Cancer Res 2011;17:3120-6
13. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104:273-9
14. Aurisicchio L, Peruzzi D, Conforti A, et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 2009;15:1575-84
15. Dangoor A, Lorigan P, Keilholz U, et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 2010;59:863-73
16. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer. Expert Opin Invest Drugs 2009;18:1001-11
17. Liu MA. DNA vaccines: An historical perspective and view to the future. Immunol Rev 2011;239:62-84
18. Ulmer JB, Otten GR. Priming of CTL responses by DNA vaccines: Direct transfection of antigen presenting cells versus cross-priming. Dev Biol 2000;104:9-14
19. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005;55:25-40
20. Chowdhery R, Gonzalez R. Immunologic therapy targeting metastatic melanoma: Allovectin-7. Immunotherapy 2011;3:17-21
21. Ribas A, Weber JS, Chmielowsli B, et al. Intra-lypmh node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: Results of a phase 1 clinical trial. Clin Cancer Res 2011;17:2987-96
22. Weber JS, Vogelzang NJ, Ernstoff MS, et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother 2011;34:556-67
23. Aurisicchio L, Ciliberto G. Emerging cancer vaccines: The promise of genetic vectors. Cancers 2011;3(3):3687-713
24. USDA licenses DNA vaccine for treatment of melanoma in dogs. J Am Vet Med Assoc 2010;236:495
25. Bergman PJ, Wolchok JD. Of mice and Men (and Dogs): Development of a xenogeneic DNA vaccine program for canine malignant melanoma. Cancer Ther 2008;6:817-26
26. Rizzuto G, Cappelletti M, Mennuni C, et al. Electro Gene-transfer results in a high level transduction of rat skeletal muscle and corrects anaemia of renal failure. Hum Gene Ther 2000;11:1891-900
27. Cappelletti M, Zampaglione I, Rizzuto G, et al. Gene electro-transfer improves transduction by modifying the fate of intramuscular plasmid DNA. J Gene Med 2003;5:324-32
28. Capone S, Zampaglione I, Vitelli A, et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 2006;177:7462-71
29. Peruzzi D Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010;28:1201-8
30. Andre F, Mir LM. DNA electrotransfer: Its principles and an updated review of its therapeutic applications. Gene Ther 2004;11:S33-42
31. Low L, Mandfer A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009;20:1269-78
32. Quaglino E, Mastini C, Amici A, et al. A better immune reaction to Erbb-2 tumors is elicide in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010;70:2604-12
33. Ross J. mRNA stability in mammalian cells. Microbiol Rev 1995;59:423-50
34. Kim CH, Oh Y, Lee TH. Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene 1997;199(1-2):293-301
35. Stratford R, Douce G, Zhang-Barber L, et al. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine 2000;19:810-15
36. Fuglsang A. Codon optimizer: A freeware tool for codon optimization. Protein Expr Purif 2003;31:247-59
37. Mennuni C, Calvaruso F, Facciabene A, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005;117:444-55
38. Aurisicchio L, Mennuni C, Giannetti P, et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 2007;120:2290-300
39. Cipriani B, Fridman A, Bendtsen C, et al. Therapeutic vaccination hapts disease progression in BALB-neuT mice. The amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 2008;19:670-80
40. Mori F, Giannetti P, Peruzzi D, et al. A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther 2009;20:125-36
41. Facciabene A, Aurisicchio L, Elia L, et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 2006;17:81-92
42. Stevenson FK, Mander A, Chudley L, Ottensmeier C. DNA fusion vaccines enter the clinic. Cancer Immunol Immunother 2011;60:1147-51
43. Facciabene A, Aurisicchio L, Elia L, et al. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 2007;26:47-58
44. Conforti A, Cipriani B, Peruzzi D, et al. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine 2010;28:3522-30
45. Dharmapuri S, Aurisicchio L, Neuner P, et al. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther 2009;16:462-72
46. Dharmapuri S, Aurisicchio L, Biondo A, et al. Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model. Hum Gene Ther 2009;20:89-97
47. Huang B, Mao CP, Peng S, et al. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008;19:763-73
48. Fotin-Mleczek M, Zanziger K, Heindereich R, et al. Kallen. Highly potent MRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med 2012;doi: 10.1002/jgm.2605. [Epub ahead of print]
49. Murray N, McMichael A. Antigen presentation in virus infection. Curr Opin Immunol 1992;4:401-7
50. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010;8:62-73
51. Walsh SR, Dolin R. Vaccinia viruses: Vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines 2011;10:1221-40
52. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17:332-7
53. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73
54. von Mehren M, Arlen Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6:2219-28
55. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomised controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105
56. Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development. Hum Vaccin 2010;6:784-91
57. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-conmtrolled phase III study. Clin Cancer Res 2010;16:5539-47
58. Zhang RT, Bines SD, Ruby C, Kaufman HL. Trovax(-) vaccine therapy for renal cell carcinoma. Immunotherapy 2012;4:27-42
59. Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial. Lancet Oncol 2011;12:1125-33
60. Quetglas JI, Ruiz-Guillen M, Aranda A, et al. Alphavirus vectors for cancer therapy. Virus Res 2010;153:179-96
61. Durso RJ, Andjelic S, Gardner JP, et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 2007;13:3999-4008
62. Moran TP, Burgents JE, Long B, et al. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 2007;25:6604-12
63. Avogadri F, Merghoub T, Maughan MF, et al. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 2010;5(9):e12670
64. Morse MA, Hobeika AC, Osada T, et al. An alphavurus vector overcomes the presence of neutralizing antibodies and elevated number of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 2010;120:3234-41
65. Smith JG, Wiethoff CM, Stewart PL, Nemerow GR. Adenovirus. Curr Top Microbiol Immunol 2010;343:195-224
66. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009;17:1333-9
67. Silva AC, Peixoto C, Lucas T, et al. Adenovirus vector production and purification. Curr Gene Ther 2010;10:437-55
68. Dharmapuri S, Peruzzi D, Aurisicchio L. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin Biol Ther 2009;9:1279-87
69. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286:2244-5
70. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93
71. Roy S, Shirley PS, McClelland A, Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 1998;72:6875-9
72. Crawford-Miksza L, Schnurr DP. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 1996;70:1836-44
73. Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35 and 48 in pediatric and adult populations. Vaccine 2011;29:5203-9
74. Vogels R, Zuijdegeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003;77:8263-71
75. Seshidar Reddy P, Ganesh S, Limbach MP, et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003;311:384-93
76. Lemckert AA, Grimbergen J, Smits S, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: Manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 2006;87:2891-9
77. Lemckert AA, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005;79:9694-701
78. Abbink P, Lemkert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007;81:4654-63
79. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived for a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012;4(115):115ra2; 1-9
80. Mennuni C, Ugel S, Mori F, et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008;68:9865-74
81. Fattori E, Aurisicchio L, Zampaglione I, et al. Her2 ErbB2 genetic cancer vaccine in non human primates: Relevance of single nucleotide polymorphisms. Hum Gene Ther 2008;20:253-65
82. Peruzzi D, Mori F, Conforti A, et al. MMP11: A novel target antigen for cancer immunotherapy. Clin Cancer Res 2009;15:4104-13
83. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006;24:849-62
84. Wuest T, Both GW, Prince AM, et al. Recombinant ovine adenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004;22:2717-21
85. Tatsis N, Tesema L, Robinson ER, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006;13:421-9
86. Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 2005;79:14595-605
87. Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 2004;105:127-36
88. Calnek BW, Shek WR, Menendez NA, Stiube P. Serological cross-reactivity of avian adenovirus serotypes in an enzyme-linked immunosorbent assay. Avian Dis 1982;26:897-906
89. Peruzzi D, Dharmapuri S, Cirillo A, et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009;27:1293-300
90. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4(115):115ra1; 1-11
91. Auer R, Bell JC. Oncolytic viruses. Smart therapeutics for smart cancers. Future Oncol 2012;8:1-473
92. Toth K, Dhar D, Wold WS. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 2010;10:353-68
93. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003;2:S157-60
94. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: The education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007;7:133-9
95. Kaufman HL, Bines SD. OPTIM trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010;6:941-9
96. Merrick AE, Ilett EJ, Melcher AA. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 2009;10:1372-82
97. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009;21:346-51
98. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482:89-93
99. Capone S, Reyes-Sandoval A, Naddeo M, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdciCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010;29:236-65
100. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011;19:2269-76
101. Peruzzi D, Gavazza A, Mesiti G, et al. A vaccine targeting telomerase enhances serviva of dogs affected by B-cell lymphoma. Mol Ther 2009;18:1559-67